Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
J Clin Gastroenterol
; 43(5): 496-8, 2009.
Article
en En
| MEDLINE
| ID: mdl-19247200
ABSTRACT
Patients who are hepatitis B surface antigen (HBsAg) positive are at risk for hepatitis flare when receiving cytotoxic or immunosuppressive therapy. It has been reported that as high as 50% of HBsAg-positive individuals who undergo chemotherapy develop elevation of liver transaminases. According to current Association for the Study of Liver Diseases guidelines, prophylactic lamivudine should be routinely administered to HBsAg-positive patients with malignancy before chemotherapy. However, occult hepatitis B virus (HBV) infection, defined as HBsAg negative and HBV DNA positive, regardless of HBV core antibody (anti-HBc) status, is not infrequent in HBV endemic areas. Here, we report the case of a B-cell non-Hodgkin lymphoma female patient who was negative for HBsAg, but positive for anti-HBc at the time of chemotherapy. Unfortunately, she developed a fatal HBV reactivation after completing the course of chemotherapy. This case highlights the potential role of lamivudine or other nucleos(t)ide analogue prophylaxis in anti-HBc-positive malignant patient who is about to undergo chemotherapy to provide better coverage for occult HBV infection.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Activación Viral
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Virus de la Hepatitis B
/
Linfoma de Células B Grandes Difuso
/
Hepatitis B
/
Anticuerpos contra la Hepatitis B
/
Antígenos del Núcleo de la Hepatitis B
/
Antígenos de Superficie de la Hepatitis B
Tipo de estudio:
Guideline
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
J Clin Gastroenterol
Año:
2009
Tipo del documento:
Article
País de afiliación:
Taiwán